MARKET

GMDA

GMDA

Gamida Cell Ltd.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.640
+0.180
+7.32%
Closed 19:34 08/10 EDT
OPEN
2.550
PREV CLOSE
2.460
HIGH
2.695
LOW
2.325
VOLUME
1.48M
TURNOVER
--
52 WEEK HIGH
5.91
52 WEEK LOW
1.480
MARKET CAP
158.36M
P/E (TTM)
-1.7036
1D
5D
1M
3M
1Y
5Y
Gamida Cell Announces Dosing Of First Patient In Company-Sponsored Phase 1/2 Study Of NK Cell Therapy Candidate GDA-201
Gamida Cell Ltd. (NASDAQ:GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announces dosing of the first patient in a
Benzinga · 23h ago
Gamida Cell Reports First Patient Dosed in Phase 1/2 Study of GDA-201 to Treat Lymphomas
Gamida Cell Reports First Patient Dosed in Phase 1/2 Study of GDA-201 to Treat Lymphomas
MT Newswires · 1d ago
These 2 Penny Stocks Are Poised for a Big Rally, Says Oppenheimer
Does high risk mean high reward? Not necessarily, so say the pros on Wall Street. Specifically citing penny stocks, or stocks that trade for less than $5 per share, analysts advise caution as these names might still be in the early innings, or it could be ...
TipRanks · 1d ago
Gamida Cell Announces the Date of Its Second Quarter 2022 Financial Results and Webcast
BOSTON, August 08, 2022--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, today announced that the company will host a conferen...
Business Wire · 2d ago
How Many Gamida Cell Ltd. (NASDAQ:GMDA) Shares Do Institutions Own?
The big shareholder groups in Gamida Cell Ltd. ( NASDAQ:GMDA ) have power over the company. Large companies usually...
Simply Wall St. · 6d ago
AEMD,GMDA and QNRX are among pre market gainers movers
AMTD IDEA (AMTD) +323%. 36Kr Holdings (<a href="https://seekingalpha.co...
Seekingalpha · 08/02 12:30
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
Benzinga · 08/01 22:41
FDA Accepts Gamida's Filing For Stem Cell Transplant Candidate Under Priority Review
The U.S. Food and Drug Administration (FDA) has accepted for filing the Gamida Cell’s (NASDAQ: GMDA) Biologics License Application (BLA) for omidubicel in the treatment of patients with blood cancers in need of an allogenic hematopoietic stem cell transpla...
Benzinga · 08/01 15:43
More
No Data
Learn about the latest financial forecast of GMDA. Analyze the recent business situations of Gamida Cell Ltd. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

16.67%Strong Buy
83.33%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average GMDA stock price target is 14.40 with a high estimate of 22.00 and a low estimate of 6.00.
High22.00
Average14.40
Low6.00
Current 2.640
EPS
Actual
Estimate
-0.42-0.31-0.21-0.10
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 67
Institutional Holdings: 18.69M
% Owned: 31.16%
Shares Outstanding: 59.98M
TypeInstitutionsShares
Increased
15
1.40M
New
5
24.92K
Decreased
18
367.55K
Sold Out
9
1.03M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.06%
Pharmaceuticals & Medical Research
+0.92%
Key Executives
Non-Executive Chairman/Independent Director
Robert Blum
Chief Executive Officer/Director
Julian Adams
Chief Financial Officer
Shai Lankry
Chief Operating Officer/Chief Compliance Officer
Michele Korfin
Chief Scientific Officer
Tracey Lodie
Other
Joshua Hamermesh
Other
Ronit Simantov
Other
Jas Uppal
Director
Ivan Borrello
Director
Anat Cohen-Dayag
Director
Naama Halevi-Davidov
Independent Director
Stephen Wills
Non-Executive Independent Director
Nurit Benjamini
Non-Executive Independent Director
David Fox
Non-Executive Independent Director
Kenneth Moch
Non-Executive Independent Director
Michael Perry
Non-Executive Independent Director
Shawn Tomasello
No Data
No Data
About GMDA
Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology to develop a pipeline of products designed to address the limitations of cell therapies. The following are the Company's clinical pipeline products: NiCord, which is evaluated in a Phase III study in patients with high-risk blood cancers as well as in a Phase SS study in patients with severe aplastic anemia, as well as NAM-NK, an innate immunotherapy for the treatment of hematologic and solid tumors, which is investigated in a Phase I investigator-sponsored trial for the treatment of relapsed or refractory non-Hodgkin lymphoma (NHL), and multiple myeloma (MM).

Webull offers kinds of Gamida Cell Ltd stock information, including NASDAQ:GMDA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GMDA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GMDA stock methods without spending real money on the virtual paper trading platform.